Phase 1 Study to Investigate the Dosimetry and Biodistribution of a Single Intravenous Administration of 99mTc-p5+14 Using SPECT/CT Imaging and Planar Gamma Scintigraphy in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Latest Information Update: 14 Feb 2025
At a glance
- Drugs Technetium-99m (Primary)
- Indications Amyloid light-chain amyloidosis; Transthyretin-related hereditary amyloidosis
- Focus Diagnostic use
- 30 May 2024 According to Attralus media release, data from this trial presented at the XIX International Symposium on Amyloidosis (ISA)
- 06 Feb 2024 According to Attralus media release, company announced that it has closed a $56 million financing. Attralus intends to use the proceeds from the financing to advance the development of this trial.
- 25 Jul 2023 New trial record